Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

por Subbiah, Vivek, Chawla, Sant P., Conley, Anthony P., Wilky, Breelyn A., Tolcher, Anthony, Lakhani, Nehal J., Berz, David, Andrianov, Vasily, Crago, William, Holcomb, Monica, Hussain, Abrahim, Veldstra, Carson, Kalabus, James, O’Neill, Brianne, Senne, Lane, Rowell, Emily, Heidt, Analeah B., Willis, Katelyn M., Eckelman, Brendan P.
Publicado 2023

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

por Aggarwal, Charu, Prawira, Amy, Antonia, Scott, Rahma, Osama, Tolcher, Anthony, Cohen, Roger B, Lou, Yanyan, Hauke, Ralph, Vogelzang, Nicholas, P Zandberg, Dan, Kalebasty, Arash Rezazadeh, Atkinson, Victoria, Adjei, Alex A, Seetharam, Mahesh, Birnbaum, Ariel, Weickhardt, Andrew, Ganju, Vinod, Joshua, Anthony M, Cavallo, Rosetta, Peng, Linda, Zhang, Xiaoyu, Kaul, Sanjeev, Baughman, Jan, Bonvini, Ezio, Moore, Paul A, Goldberg, Stacie M, Arnaldez, Fernanda I, Ferris, Robert L, Lakhani, Nehal J
Publicado 2022